- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02320227
A Single-Center, Clinical Study to Evaluate the Safety of a Non-Fragranced Personal Lubricant in Healthy Female Subjects
January 30, 2017 updated by: Church & Dwight Company, Inc.
To evaluate the safety of a personal lubricant when used as indicated as a personal lubricant in the vagina and vulvar/perineal areas at least four times weekly for two weeks in a population of healthy females
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
Piscataway, New Jersey, United States, 08854
- Clinical Research Laboratories
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Subject is female between the ages of 18 and 49 years (at lease 21 subjects) or 50-60 years (no more than 9 subjects);
- Subject is using adequate non-barrier method of birth control [established us of hormonal methods of contraception (oral, injected, implanted, or patch), intrauterine device (IUD) or intrauterine system (IUS), surgical sterilization (e.g. in a monogamous relationship with male partner with vasectomy];
- Subject is free of any vaginal disorders;
- Subject is sexually active and in a monogamous, heterosexual relationship, and whose male partner is willing and able to give informed consent and agrees to engage in sexual intercourse at least twice each week during the two-week study (at least 50% and up to 100% of the study population) or is not sexually active (no more than 50% of the population);
- Subject is a personal lubricant user and agrees to replace her usual personal lubricant with the investigational product;
- Subject has normal menstrual cycle and is not expected to menstruate 2-4 days before or after the examination days;
- Subject agrees to use the provided investigational product at least four times weekly (including at least twice weekly during sexual intercourse for subjects with monogamous, male partners) over the two-week study period;
- Subject exhibits no clinically significant evidence of vulvar or vaginal irritation, as determined by a study doctor, and no reports of sensory irritation at the baseline examination;
- Subject is willing to refrain from introducing any new vaginal products, or using vaginal medication or local contraceptives (including condoms and hormonal rings), during the course of this study;
- Subject agrees to refrain from douching or using any medications, powder, lotions or personal care products in the vulvar or perianal area for the duration of the study (Note: subjects may continue to use their usual pantyliner, if any);
- Subject is willing to use a urine pregnancy test provided to them at baseline and on the third visit (Week 2, day 14);
- Subject has a standard Clinical Research Laboratories, Inc. (CRL) Medical History form on file at CRL and has completed study specific Medical History and Screener/Inclusion forms;
- Subject has signed and, if sexually active and in a monogamous relationship, whose partner has signed, an Informed Consent Form (ICF) in compliance with 21 CFR Part 50: "Protection of Human Subjects";
- Subject (and male partner, if applicable) has completed a HIPAA Authorization Form in conformance with 45 CFR Parts 160 and 164;
- Subject is dependable and able to follow directions as outlined in the protocol;
- Subject receives a score of 0 or 0.5 for erythema and edema, and 0 for sensorial irritation (burning, stinging, itching, and dryness) during the first examination.
Exclusion Criteria:
- Subject is pregnant, nursing, or planning a pregnancy;
- Subject is post-menopausal or has had a hysterectomy;
- Subject is currently using, or has used within two weeks prior to study initiation, any systemic or topical corticosteroids, vasoconstrictors, antibiotics, anti-inflammatories, or antihistamines;
- Subject has known allergies to vaginal or any cosmetic products (including lotions, moisturizer, powder, sprays, etc.);
- Subject reports a history of recurrent bladder, vaginal infection, or incontinence;
- Subject exhibits or reports gynecological abnormalities or has had vaginitis within 60 days prior to study initiation.
- Subject is expected to menstruate 2-4 days before or after the time of the first, second, and third examination;
- Subject uses a vaginal ring, diaphragm or cervical/vault caps, condoms, or condoms with spermicide as a means of contraception;
- Subject has participated in a study involving the vaginal area or in an investigational systemic drug study within two weeks of study initiation;
- Subject receives a score higher than 0.5 for erythema, edema, or >0 for burning, stinging, or itching, during the first examination or shows any other sign of mucosal irregularities (dryness, papules, vesticulation, fissure).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Miami w/o frag Personal lubricant
Healthy subjects use Miami w/o frag Personal lubricant at least 4 times per week for 2 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Observed Local Erythema
Time Frame: 14 Days
|
Number of participants with observed local erythema by OB/GYN examination.
|
14 Days
|
Number of Participants With Observed Local Edema
Time Frame: 14 days
|
Number of participants with observed edema by OB/GYN examination.
|
14 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2014
Primary Completion (Actual)
January 1, 2015
Study Completion (Actual)
January 1, 2015
Study Registration Dates
First Submitted
December 9, 2014
First Submitted That Met QC Criteria
December 16, 2014
First Posted (Estimate)
December 19, 2014
Study Record Updates
Last Update Posted (Actual)
March 10, 2017
Last Update Submitted That Met QC Criteria
January 30, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ST-7557
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Edema
-
Eye-yon MedicalCompletedCORNEAL EDEMAIsrael, Poland
-
Federico II UniversityCompletedPseudophakic Cystoid Macular Edema
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletedDiabetic Macular Edema | Cystoid Macular EdemaUnited States
-
Postgraduate Institute of Medical Education and...CompletedDiabetic Macular Edema | Vision Disorders | Macular Edema, Cystoid | Clinically Significant Macular EdemaIndia
-
National Cardiovascular Center Harapan Kita Hospital...CompletedMyocardial Edema
-
OcugenNot yet recruitingDiabetic Macular Edema | Center Involved Diabetic Macular Edema
-
Ellianne M. NasserRecruitingBone Marrow EdemaUnited States
-
OculisICON plcRecruitingDiabetic Macular EdemaUnited States
-
Novartis PharmaceuticalsNot yet recruiting
Clinical Trials on Miami w/o frag Personal lubricant
-
Church & Dwight Company, Inc.CompletedEdema | ErythemaUnited States
-
Church & Dwight Company, Inc.CompletedCumulative IrritationUnited States